Samra Turajlic

Royal Marsden NHS Foundation Trust — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

53h-index20.2kcitations336works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(112), Cancer Immunotherapy and Biomarkers(76), Renal cell carcinoma treatment(72), Melanoma and MAPK Pathways(61), Cutaneous Melanoma Detection and Management(35)

Publications330 total

Cross-presentation of dead cell-associated antigens shapes the neoantigenic landscape of tumor immunity
Nature Immunology·2026· 1 citedOpen Access
TRACERx as an Optimized Paradigm for Understanding Cancer Evolution
Annual Review of Cancer Biology·2025
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials
European Urology Open Science·2025Open Access
Supplementary Tables S1-S8 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2025Open Access
Supplementary Figures S1-S25 from Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways
2025Open Access
Somatic evolution following cancer treatment in normal tissue
Nature·2025Open Access
Immunometabolic Gatekeeping: Reconciling Peto's & the T-cell Infiltration Prognostic Paradox
arXiv (Cornell University)·2025Open Access
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
The Lancet Oncology·2025· 4 citedOpen Access
Abstract A002: Comprehensive blood profiling for immunotherapy outcome prediction and longitudinal immune trajectory characterisation
Cancer Immunology Research·2025
Publisher Correction: TCF1 and LEF1 promote B-1a cell homeostasis and regulatory function
Nature·2025Open Access
109O Capturing clonal evolution through histology
Annals of Oncology·2025
TCF1 and LEF1 promote B-1a cell homeostasis and regulatory function
Nature·2025· 2 citedOpen Access
Uveal Melanoma UK national guidelines: 2023 update
European Journal of Cancer·2025· 3 citedOpen Access
Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist
Journal of Neurology Neurosurgery & Psychiatry·2025· 2 citedOpen Access
Combining Immunotherapies With Standard Therapies in the Treatment of Cancer
Elsevier eBooks·2025
Supplementary File from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
Supplementary Table 1 from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
MANIFEST: Multiomic Platform for Cancer Immunotherapy
Cancer Discovery·2025· 3 citedOpen Access
Data from MANIFEST: Multiomic Platform for Cancer Immunotherapy
2025Open Access
Fatal intracranial haemorrhage shortly after belzutifan initiation in von Hippel–Lindau (VHL) disease-associated haemangioblastoma
ESMO Open·2025· 2 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

James Larkin(32), Charles Swanton(28), Lewis Au(18), Martin Gore(16), Andrew Rowan(15), Lavinia Spain(15), Lisa Pickering(15), Nicholas McGranahan(14), Hang Xu(14), Sophia Ward(13), Kevin Litchfield(13), Sergio A. Quezada(12), Stuart Horswell(11), Rachel Rosenthal(10), Andrew J.S. Furness(10), Gordon Stamp(10), Fiona Byrne(10), Annika Fendler(10), Mariam Jamal‐Hanjani(9), Nicolai J. Birkbak(9)